Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK**

By Davies Andrew   Vardeva Kawitha   Loze Jean-Yves   L’’Italien Gilbert J.   Sennfalt Karin   Baardewijk Marc van  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3275-3285

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data

By Frey Simon   Linder Roland   Juckel Georg   Stargardt Tom  

The European Journal of Health Economics, Vol. 15, Iss. 2, 2014-03 ,pp. : 133-142

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

By Heeg B. M. S.   Antunes J.   Figueira M. L.   Jara J. M.   Marques Teixeira J.   Palha A. P.   Vaz Serra A.   Buskens E.   Caleo S.   Gouveia-Pinto C.   Van Hout B. A.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 349-358

Informa Healthcare

Access to resources Recommend Favorite

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

By Lafeuille Marie-Hélène   Gravel Jonathan   Lefebvre Patrick   Fastenau John   Muser Erik   Doshi Dilesh   Duh Mei Sheng  

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1290-1299

Informa Healthcare

Access to resources Recommend Favorite

Meta-Analysis of the Effectiveness of Atypical Antipsychotics for the Treatment of Behavioural Problems in Persons with Dementia

By  

Psychotherapy and Psychosomatics, Vol. 76, Iss. 4, 2007-06 ,pp. : 213-218

Karger

Access to resources Recommend Favorite